Pathological Role of Interleukin-6 in Psoriatic Arthritis

  • Ogata A
  • Kumanogoh A
  • Tanaka T
N/ACitations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Psoriatic arthritis (PsA) is a clinical manifestation of psoriatic disease. Although the pathogenesis of PsA remains unknown, PsA can be managed by treatments similar to those used for rheumatoid arthritis (RA). Because interleukin-(IL-) 6 has been suggested to have a pathogenic role in PsA, a humanized anti-IL-6 receptor antibody tocilizumab treatment for PsA was recently tried. However, the efficacy of tocilizumab for PsA was not favorable. This suggests that the pathogenic roles of IL-6 in PsA and RA are different. In RA, tumor necrosis factor (TNF) primarily contributes to the arthritis effector phase and IL-6 contributes to the arthritis priming phase. In PsA, the TNF-related effector phase is similar to that in RA, but the IL-6-related priming phase might not be critical. This paper discusses the role of IL-6 in PsA.

Cite

CITATION STYLE

APA

Ogata, A., Kumanogoh, A., & Tanaka, T. (2012). Pathological Role of Interleukin-6 in Psoriatic Arthritis. Arthritis, 2012, 1–6. https://doi.org/10.1155/2012/713618

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free